Home » Stocks » JANX

Janux Therapeutics, Inc. (JANX)

Stock Price: $23.21 USD 1.17 (5.31%)
Updated Jun 23, 2021 4:00 PM EDT - Market closed
Market Cap 837.92M
Revenue (ttm) 380,000
Net Income (ttm) -7.66M
Shares Out 36.10M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 23
Last Price $23.21
Previous Close $22.04
Change ($) 1.17
Change (%) 5.31%
Day's Open 22.30
Day's Range 21.44 - 23.40
Day's Volume 153,391
52-Week Range 16.32 - 37.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LA JOLLA, Calif.--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previo...

1 week ago - Business Wire

The 37th biotech to hit the public markets this year has a potentially $1 billion deal with Merck & Co. Inc. ( MRK , Financial).

Other stocks mentioned: MRK
1 week ago - GuruFocus

Janux Therapeutics, Inc. (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the pricing of its initial public offering of 11,400,000 shares of its comm...

1 week ago - Business Wire

Janux Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About JANX

Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on our proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Our initial focus is on developing a novel class of T cell engagers (TCEs), an emerging class of immunotherapies that bridge a tumor cell and a T cell, to activate and redirect T cells to attack and eliminate tumors, and our lead product candidates are designed to target clinically validated drug targets. We are d... [Read more...]

Industry
Biotechnology
IPO Date
Jun 11, 2021
CEO
David Campbell, Ph.D.
Employees
16
Stock Exchange
NASDAQ
Ticker Symbol
JANX
Full Company Profile

Financial Performance

Financial Statements